Liquid Biopsy Market Overview:
Liquid Biopsy Market is projected to be worth USD 24.14 Billion by 2030, registering a CAGR of 13.7% during the forecast period (2022-2030), the market was valued at USD 7.60 Billion in 2021.
A liquid biopsy Market is a non-invasive test that analyzes blood or other bodily fluids to detect cancer or other diseases. It can be used to diagnose, monitor, and potentially treat cancer by detecting cancer-specific DNA or other biomarkers in the blood.
Liquid biopsy is widely used in various applications such as cancer diagnosis and treatment monitoring, prenatal testing, transplant diagnostics, and infectious disease diagnosis. The development of new technologies such as ctDNA, cfRNA, and exosomes has expanded the scope of liquid biopsy beyond traditional applications.
The increasing prevalence of cancer worldwide is one of the important drivers of the liquid biopsy market. Liquid biopsy provides a non-invasive and cost-effective alternative to traditional biopsy procedures, making it a preferred choice for cancer diagnosis and treatment monitoring.
Get Sample Report Here: https://marketresearchcommunity.com/sample-request/?rid=662
The study is consolidated into major segments and further into sub-segments, such as by technology (multi-gene-parallel analysis (NGS), single gene analysis (PCR microarrays), sample type (blood sample-based, others) biomarker (circulating nucleic acids, CTC, exosomes/microvesicles, circulating proteins) to forecast the market size by value.
Key segments
By technology
- multi-gene-parallel analysis (NGS)
- single gene analysis (PCR microarrays
By sample Type
- blood sample-based
- others
By Biomarker
- circulating nucleic acids
- CTC
- exosomes/microvesicles
- circulating proteins
By Region:
- North America– (U.S., Canada, Mexico
- Europe- (Germany, France, U.K., Russia, Italy, Spain, BENELUX, Rest of Europe)
- Asia Pacific- (China, Japan, India, South Korea, Australia, ASEAN, Rest of Asia Pacific)
- Latin America- (Brazil, Argentina, Chile, Rest of Latin America)
- Middle East and Africa- (GCC, Turkey, Israel, Rest of MEA)
Lastly, the report includes a regional analysis and country analysis with the latest Liquid Biopsy Market Trends, along with the major key players including Illumina, Inc; Angle plc; Oncimmune; Thermo Fisher Scientific, Inc.; Lucence health Inc.; Freenome holdings, Inc.; Epigenomics AG, QIAGEN; Myriad Genetics, Inc; BIOCEPT, Inc; Guardant Health, Inc; F. Hoffmann-La Roche Ltd.
Contact:
Market Research Community
Email: [email protected]
